1,143
Participants
Start Date
December 31, 2006
Primary Completion Date
January 31, 2009
Study Completion Date
September 30, 2011
150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)
150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
NYU Medical Center Family Planning Division, New York
Columbia University, New York
Magee-Womens Hospital, Pittsburgh
University of Pennsylvania Medical Center, Philadelphia
Contraceptive Research and Programs, Baltimore
Jones Institute of Repro Medicine, EVMS, Norfolk
The Ohio State University, Columbus
MacDonald Physicians, Inc., Cleveland
University of Cincinnati College of Medicine, Cincinnati
UT Southwestern Medical Center; Division of Community Women's Health Care, Dallas
University of Colorado - Adv. Repro. Med., Denver
California Family Health Council, Los Angeles
Oregon Health Sciences University, Portland
University of Kentucky, Lexington
Baystate Medical Center, Springfield
Lead Sponsor
Population Council
OTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Premier Research
OTHER